Tracon Pharmaceuticals has terminated the Phase II ENVASARC trial for its sarcoma therapy, envafolimab, as the therapy is unlikely to show the level of efficacy required to support a biologics licence ...
SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to ...
The Federal Aviation Administration’s decision last year to move some air traffic controllers from Westbury to Philadelphia came with complications and consequences, from the impact on Long Island ...
SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results